Onvatilimab, designated as JNJ-61610588, represents a novel medicinal antibody targeting {PD-1 | the PD-1 molecule ) and currently undergoing evaluation for a range of {cancer | malignant diseases ) indications . This designed IgG4 monoclonal antibody exhibits considerable potential in inhibiting PD-1 engagement with its partners, thus activating T